

<b>Clinical Policy Title:</b>	abrocitinib
<b>Policy Number:</b>	RxA.752
<b>Drug(s) Applied:</b>	Cibinqo™
<b>Original Policy Date:</b>	04/18/2022
<b>Last Review Date:</b>	08/28/2024
<b>Line of Business Policy Applies to:</b>	All lines of business (except Medicare)

## Criteria

### I. Initial Approval Criteria

#### A. Moderate to severe atopic dermatitis (must meet all):

1. Diagnosis of moderate to severe atopic dermatitis;
2. Documentation of involvement of at least 10% of body surface area;
3. Trial and failure of both the following (a and b):
  - a. One medium to high potency topical corticosteroid or topical calcineurin inhibitor;
  - b. One systemic agent (ie. Adbry or Dupixent).

#### Approval Duration

**All Lines of Business (except Medicare):** 6 months

### II. Continued Therapy Approval

#### A. Moderate to severe atopic dermatitis (must meet all):

1. Auto-approval based on lookback functionality within the past 120 days as a proxy for member responding positively to therapy.

#### Approval Duration

**All Lines of Business (except Medicare):** 12 months

## References

1. David M Fleischer, MD; Jeremy Udkoff, MA, Atopic dermatitis: skin care and topical therapies. Seminar in cutaneous medicine and surgery, September 2017, Vol 36, No. 3. Available at: [https://nationaleczema.org/wp-content/uploads/2018/03/258887\\_eprint4.pdf](https://nationaleczema.org/wp-content/uploads/2018/03/258887_eprint4.pdf). Accessed August 28, 2024.
2. Dermatitis. Topical calcineurin inhibitors | dermnet nz. Available at: <https://dermnetnz.org/cme/dermatitis/topical-calcineurin-inhibitors>. Accessed August 28, 2024.

Review/Revision History	Review/Revision Date	P&T Approval Date
Policy established.	03/08/2022	04/18/2022
<ol style="list-style-type: none"> <li>1. Initial Approval Criteria, I. A.2: Updated age criteria from Age ≥18 years to Age ≥12 years;</li> <li>2. References were reviewed and updated.</li> </ol>	3/28/2023	04/13/2023

This clinical policy has been developed to authorize, modify, or determine coverage for individuals with similar conditions. Specific care and treatment may vary depending on individual need and benefits covered by the plan. This policy is not intended to dictate to providers how to practice medicine, nor does it constitute a contract or guarantee regarding payment or results. This document may contain prescription brand name drugs that are trademarks of pharmaceutical manufacturers that are not affiliated with RxAdvance.

Policy was reviewed.	10/19/2023	10/19/2023
Policy was reviewed: <ol style="list-style-type: none"> <li>1. Removed age requirement.</li> <li>2. Removed trial and failure requirement for phototherapy.</li> <li>3. Removed trial and failure criteria for Dupixent.</li> <li>4. Removed coadministration criteria.</li> <li>5. Removed dosing criteria.</li> <li>6. Removed 'positive response to therapy' criteria from reauthorization.</li> <li>7. References were reviewed and updated.</li> </ol>	02/01/2024	02/01/2024
Policy was reviewed: <ol style="list-style-type: none"> <li>1. Removed prescriber restrictions.</li> <li>2. Updated Continued therapy approval with auto-approval based on lookback functionality within the past 120 days.</li> <li>3. Updated approval duration verbiage.</li> <li>4. References were reviewed and updated.</li> </ol>	08/28/2024	9/13/2024